CALCITONIN GENE-RELATED PEPTIDE RECEPTOR (CGRP-R) ANTAGONIST
Emgality is approved by the Food and Drug Administration (FDA) to prevent migraine in adults. Emgality is also referred to by its drug name, Galcanezumab-gnlm.
Emgality is a biologic drug – a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Emgality is also a member of a new class of drugs called calcitonin gene-related peptide receptor (CGRP-R) antagonists. Emgality is believed to work by interfering with CGRP, a substance that dilates blood vessels and contributes to pain signals and inflammation.
How do I take it?
Prescribing information states that Emgality is administered as a subcutaneous injection once a month after initial loading doses.
Emgality comes in prefilled, single-dose syringes and pens.
The FDA-approved label for Emgality lists injection site reactions as a common side effect.
Because Emgality is a new drug, its long-term effects are not yet known.
For more details about this treatment, visit:
Emgality.com – Lilly
FDA Greenlights Galcanezumab (Emgality) for Migraine Prevention – Medscape